Management Strategies of dermatomyositis during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)

Abstract In late 2019, the coronavirus disease 2019 (COVID-19) broke out in Wuhan and then spread over China, which greatly impacted on the medical practices and healthcare systems. With most of the hospital's outpatient services closed, the routine clinical diagnosis and treatment for dermatomyositis (DM) patients has been disturbed. We conducted telephone follow-up on 52 patients to concern the changes in the condition and the continuation of drug therapy, to ensure the continuity, safety and effectiveness treatment of DM patients during COVID-19.